Tesamorelin
Egrifta · TH9507
FDA-approved GHRH analogue specifically studied for visceral fat reduction in HIV-associated lipodystrophy, with broader anti-aging research interest.
Half-Life
~26-38 minutes
MW
5136.0 Da
Amino Acids
44 AA
Evidence
High Evidence
Regulatory Status
FDA-approved for HIV-lipodystrophy (Egrifta). Off-label use is research.
In Plain English
A GHRH analog specifically designed and FDA-approved for reducing deep belly fat in HIV patients. It raises GH enough to burn visceral fat without the risks of injecting actual growth hormone.
Overview
Tesamorelin is a synthetic stabilized analogue of GHRH. It is FDA-approved (Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It has broader interest as an anti-aging and body composition tool due to its GH-stimulating properties.
Common Formats
- Lyophilized powder (injectable)
Storage Notes
Refrigerate. Reconstituted: use within 24 hours (pharmaceutical), longer for research grade.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Tesamorelin.
Related Compounds
Sermorelin
A 29-amino acid truncated analogue of endogenous GHRH, FDA-approved for pediatric GHD and widely researched for anti-aging and body composition.
CJC-1295
A long-acting GHRH analogue with a Drug Affinity Complex that extends its half-life dramatically, allowing weekly dosing for sustained GH elevation.
Ipamorelin
A highly selective GH secretagogue and ghrelin receptor agonist known for clean GH release without significant cortisol or prolactin stimulation.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.